Literature DB >> 20298138

Diagnostic performance of anti-citrullinated peptide antibodies for the diagnosis of rheumatoid arthritis: the relevance of likelihood ratios.

Donatello Pietrapertosa1, Barbara Tolusso, Elisa Gremese, Maria Concetta Papalia, Silvia Laura Bosello, Giusy Peluso, Luca Petricca, Alessandro Michelutti, Francesca Faustini, Anna Laura Fedele, Gianfranco Ferraccioli.   

Abstract

BACKGROUND: The goal of our study was to evaluate the diagnostic performance of the anti-cyclic citrullinated peptide 2 (anti-CCP2) assay in patients with autoimmune and inflammatory disorders.
METHODS: We tested the specificity and sensitivity of anti-CCP2 antibodies measured by ELISA in 787 patients with rheumatoid arthritis (RA), 1024 patients with other autoimmune/inflammatory rheumatic disease and 401 subjects without autoimmune rheumatic disease. The optimal cut-off value was defined as the value with the highest diagnostic accuracy (receiver operating characteristic curve analysis). Interval-specific likelihood ratios (LRs) were calculated for each range bounded by defined anti-CCP2 values.
RESULTS: To distinguish between patients with RA and controls, the cut-off value with the highest diagnostic accuracy for anti-CCP2 was 2.8 U/mL. Comparing the optimal cut-off value for anti-CCP2 to that recommended by the manufacturer (5.0 U/mL), an increase in prevalence between the proportions of test-positive patients was found for RA, undifferentiated connective tissue disease and undifferentiated arthritis. Evaluating interval-specific LRs for the selected ranges bound by two anti-CCP2 values, in RA and diseased controls, the LRs were 0.40 for values <5.0 U/mL, 6.66 for 5.0-15.0 U/mL, 27.01 for 15.1-30.0 U/mL and 28.89 for >30.0 U/mL.
CONCLUSIONS: The cut-off value of 2.8 U/mL for anti-CCP2 has the highest diagnostic accuracy. A value of anti-CCP2 >15 U/mL is associated with an increase in the likelihood of RA disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20298138     DOI: 10.1515/CCLM.2010.152

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  6 in total

1.  Pathogenetic, clinical and pharmaco-economic assessment in rheumatoid arthritis (RA).

Authors:  Gianfranco Ferraccioli; Elisa Gremese
Journal:  Intern Emerg Med       Date:  2011-10       Impact factor: 3.397

2.  Discriminative and diagnostic value of anti-cyclic citrullinated peptide antibodies in Iranian patients with rheumatoid arthritis.

Authors:  Jamileh Moghimi; Raheb Ghorbani; Farnaz Hasani; Mehrdad Sheikhvatan
Journal:  Rheumatol Int       Date:  2012-04-03       Impact factor: 2.631

3.  The challenge of using the rheumatoid arthritis diagnostic criteria in clinical practice.

Authors:  Salvatore Corrao; Christiano Argano; Luigi Calvo; Giovanni Pistone
Journal:  Intern Emerg Med       Date:  2015-02-12       Impact factor: 3.397

4.  Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study.

Authors:  Elisa Gremese; Fausto Salaffi; Silvia Laura Bosello; Alessandro Ciapetti; Francesca Bobbio-Pallavicini; Roberto Caporali; Gianfranco Ferraccioli
Journal:  Ann Rheum Dis       Date:  2012-07-13       Impact factor: 19.103

5.  ACPA-positive primary Sjögren's syndrome: true primary or rheumatoid arthritis-associated Sjögren's syndrome?

Authors:  J Payet; R Belkhir; J E Gottenberg; E Bergé; F Desmoulins; O Meyer; X Mariette; R Seror
Journal:  RMD Open       Date:  2015-04-30

6.  Anti-Cyclic Citrullinated Peptide Antibody as a Predictor of Rheumathoid Arthritis Complications.

Authors:  Mevludin Mekic; Emina Hadzigrahic
Journal:  Med Arch       Date:  2020-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.